Presented at 53rd American College of Neuropsychopharmacology Annual Meeting Tokyo, Dec 10, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has presented data from a Phase II clinical study (Study 201) on its in-house-developed investigational dual orexin receptor antagonist (DORA) E2006 in patients with insomnia disorder at the 53rd American College of Neuropsychopharmacology (ACNP) Annual Meeting held from December 7 through 11, 2014, in Phoenix, Arizona in the United States. In the study, E2006 demonstrated a statistically significant improvement in sleep initiation and sleep maintenance without increasing next-day residual...
↧